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Ginseng has long been used as a functional food or therapeutic supplement and it is empirically known
to be safe and nontoxic. During recent decades, a number of in vitro and in vivo experiments, as well as
human studies have been conducted to prove the safety of various types of ginseng samples and their
components. Clinical trials, case reports, and in vitro and in vivo research articles addressing the safety,
toxicity, and other adverse events of ginseng application were selected and reviewed. Patient risks
associated with ginseng abuse and misuse such as affective disorder, allergy, cardiovascular and renal
toxicity, genital organ bleeding, gynecomastia, hepatotoxicity, hypertension, reproductive toxicity, and
anticoagulant-ginseng interaction were reviewed and summarized. There are some cases of patient risk
associated with ginseng abuse and misuse depending on patients’ conditions although further investi-
gation in more cases is required to clarify these issues.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Ginseng has been used as a tonic and panacea in Asian countries
for a long time and also as a functional food or therapeutic sup-
plement in Western countries in recent times [1e7]. During the
past few decades, a number of in vitro and in vivo experiments, as
well as human studies have been conducted to prove the safety of
various types of ginseng and their components.
In animals, toxic episodes of ginseng components or prepara-
tions have been reported on several occasions [8e11], although no
short term or long term toxicities were observed in other experi-
ments [12e15].
In humans, Panax ginseng is associated with mild toxicity and
few adverse events have been reported. Siegel [16] described the
unfavorable symptoms of ginseng based on the 2-yr follow up of
133 patients with ginseng ingestion: morning diarrhea (35%), skin
eruption (25%), nervousness (25%), sleeplessness (20%), hyperten-
sion (17%), edema, decreased appetite, depression, and hypotension
(w10%). The adverse events have been associated with high doses
and long-term usage [17]. The toxicity assessment of ginseng
preparations in human studies suggested that a relatively lowgy, College of Medicine, Hanyang
e).
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application although ginseng is not without capabilities of toxicity
[18]. In addition, studies based on the systematic literature analysis
suggest that P. ginseng is infrequently related with toxic side effects
or interactions with prescription drugs [19e21]. Overall, it is
assumed that ginseng is a safe and nontoxic material although the
safety issues still remain to be elucidated.
However, there is some evidence of patient risk associated with
ginseng abuse and thus case reports and research articles
addressing the safety issues of ginseng were collected and
described in this review.
2. Affective disorder
A manic episode by ginseng intake was observed in a 56-yr-old
woman with previous affective disorder. Symptoms was wiped out
quickly with low doses of neuroleptics and benzodiazepines after
quitting ginseng preparation [22]. Similarly, a manic symptom was
developed in a 26-yr-old healthy individual with no history of
psychiatric illness after consumption of Chinese ginseng capsule for
2 mo [23].University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 133-791, Korea.
ished by Elsevier. All rights reserved.
J Ginseng Res 2015;39:89e93903. Allergy
Anaphylaxis is a serious allergic response that has fast onset and
may result in death. It is typically characterized by a number of
symptoms including an itchy rash, throat swelling, and low blood
pressure. Common causes include insect bites/stings, foods, and
medications [24]. Numerous research results suggest that various
types of ginseng and its components can efﬁciently prevent or
inhibit the experimentally-induced allergic reactions [25e28] and
the symptoms of atopic [29] and allergic rhinitis patients [30].
However, several case reports that ginseng is able to cause
allergic reactions in human have also been described. In a case
report of possible anaphylactic reaction to ginseng, a 20-yr-old
male patient was exposed to Asian ginseng syrup by consumption,
and developed respiratory allergy, erythematous papules, and
angioedema in the body and low blood pressure [31]. Another case
of anaphylactic reaction caused by P. ginseng was reported in a 29-
yr-old female patient, who had beenworking in a herbal market for
the past 26 mo and admitted to the emergency for respiratory
distress symptom. The patient respond positively to a bronchial
provocation and to a skin-prick test with ginseng-derived proteins.
This conﬁrmed that the asthma was consequent to the exposure to
Korean ginseng dust and was induced via non-immunoglobulin (Ig)
E mechanism [32]. Similarly, in a 44-yr-old man, open oral chal-
lenge with Korean ginseng extract induced the anaphylactic reac-
tion by the IgE-independent activation of basophil and mast cell
[33].
A 34-yr-old woman who was working at a Korean ginseng
wholesale market developed recurrent dyspnea and nasal symp-
toms. Skin prick test and elevated serum anti-Korean ginseng
speciﬁc IgE level showed that Korean ginseng is able to induce
occupational asthma in an individual exposed to dried ginseng and
ginseng dust for long periods [34].
Thus, it is probable that ginseng may cause an anaphylactic re-
action via the IgE-dependent or independent manners in a certain
type of individuals who might be predisposed or sensitized in
advance to ginseng, although it is not widely observed.4. Cardiovascular and renal toxicity
Long QT syndrome is a hereditary or acquired heart disorder
characterized by a prolongation of the QT interval on electrocar-
diograms and a predisposition to ventricular tachyarrhythmias,
which may lead to syncope, seizures, cardiac arrest, or sudden
death. Application of certainmedications causes QT prolongation in
some individuals [35].
Regarding this issue, in a prospective, randomized, double-
blind, placebo-controlled study, thirty subjects were randomly
grouped to receive 28 d of treatment with either P. ginseng extract
200 mg or placebo. Subsequent electrocardiogram were recorded
following test drug consumption at 50 min, 2 h, and 5 h on Day 1
and Day 28. Blood pressures were measured with each electrocar-
diogram. Ginseng extract, at daily doses of 200 mg, prolongs the
QTc interval and reduces diastolic blood pressure 2 h after con-
sumption in healthy adults on the 1st d of treatment. However, the
observed effects are not seemed to be clinically relevant [36].
Another case was reported that a 43-yr-old healthy woman patient
without cardiovascular risk factors who developed prolonged QT
with subsequent torsades de pointes during periods in which she
was abusing P. ginseng on the daily basis for 6 mo [37]. In addition,
an atrial ﬁbrillation (AF) with slow ventricular rate developed after
taking Asian ginseng for 1 wk in 83-yr-old womanwith old chronic
renal disease [38]. However, these are the very individual reactions
based on a speciﬁc condition of the onewho suffers it. Thus, cautionis needed for patients showing idiosyncrasy toward certain drugs
or functional foods.
In experiments with isolated rat aorta and primary vascular
smooth muscle cells that evaluate the effects of Rg3 on the vascular
contractility and its structure, a normally unattainable, high dose of
Rg3 induced irreversible damage of agonist-mediated vascular
contractility via blocking the calcium ion inﬂux through L-type
calcium channel. In addition, functional abnormalities and
remodeling of vascular smooth muscle were also observed by the
repeated intravenous application of high dose (20 mg/kg, 4 wk) of
Rg3 [9].
It is known that kidney dysfunction increases the risk of death
and cardiovascular disease [39]. In searching for the link between
ginseng intake and cardiovascular adverse event in renal disease, a
case was reported that an 83-year-old woman with chronic renal
insufﬁciency developed atrial ﬁbrillation with bradycardia after
ingesting ginseng for 1 wk [38]. In addition, scrutinizing the effects
of long-term use of ginseng on blood pressure and renal function,
another randomized, placebo-controlled, double-blinded, cross-
over trial in 52 hypertensive individuals was performed. Twenty-
four h blood pressure and concentration of serum cystatin C were
measured after 12 wk of American ginseng consumption. The
concentration of cystatin C is primarily used as an index of renal
function. Recently, its possible application in expecting new-onset
or deteriorating cardiovascular disease has been explored. The data
suggested that long-term ginseng ingestion does not cause any
inﬂuences on 24-h blood pressure and kidney function in hyper-
tensive individuals [40].
5. Gynecomastia and genital organ bleeding
It has been repeatedly noted that P. ginseng is able to exert
estrogen-like actions, because ginsenosides, the major compo-
nents of ginseng, have structural similarity with the female sex
hormone, estradiol [41]. Thus, ginseng has been used as an alter-
native medicine for treating postmenopausal symptoms although
its effects are still controversial [42e44]. This might lead physi-
cians to suspect the ginseng-induced gynecomastia in a man who
has ingested ginseng for a long period. Since the ﬁrst report of the
gynecomastia associated with ginseng use [45], another case has
been reported. A 12-yr-old boy was diagnosed with bilateral
enlargement of the breasts with tenderness in the right breast,
which was noticed after consumption of red ginseng extract daily
for 1 mo. After discontinuation of this, there was no further
progress in the growth of masses and in the development of pain
when his right breast was pressed [46].
A 39-yr-old woman complained of menometrorrhagia. She had
been using oral ginseng powder (1000e1500 mg/d) and, at the
same time, ginseng cosmetics for 7 mo. By examining the clinical
progress of this patient, the authors assumed that the menome-
trorrhagia is due to the misuse of ginseng although this could be
coincidental [47]. Similar case of uterine bleeding episode was re-
ported with the consumption of ginseng-containing preparation
[48].
Regarding phytoestrogen activity of ginseng, there are several
lines of evidence indicating that ginseng activates estrogen re-
ceptors. For instance, ginsenosides activate estrogen receptors in a
ligand-independent manner [49,50]. Korean Red Ginseng extract
activates estrogen receptor in vitro [51]. However, these effects are
not compatible with the observation that ginseng extract did not
affect the uterine weight in ovariectomized animals [51,52]. In
addition, in a human endometrial adenocarcinoma cell line, Ishi-
kawa, which contains an estrogen sensitive-alkaline phosphatase
enzyme, no estrogen-like action was observed by stimulation with
maximum concentration (25 mg/mL) of ginseng extract [53]. Thus,
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and gynecomastia is due to the estrogenic activity of ginseng?
Further investigation in more cases is required to clarify these
issues.
6. Hepatotoxicity
A case study reported that a 26-yr-old male leukemia patient
taking the antileukemia drug imatinib 400 mg/d for 7 yr without
adverse effects consumed ginseng energy drinks at the same time
for 3 mo and then suffered from right upper abdominal pain. After
liver biopsy, it turned out to be acute lobular hepatitis. The author
claims that the late onset of imatinib-induced hepatotoxicity is not
probable since severe imatinib-induced hepatotoxicity is rather
uncommon and it usually takes place within 1e2 years after initi-
ation of therapy [80,81]. And thus, the hepatotoxicity is due to the
interaction between ginseng and imatinib inwhich ginseng inhibits
CYP3A4, the primary enzyme involved in the metabolism of ima-
tinib, thereby it causes rise in concentration of imatinib to the toxic
level [54].
However, it has been suggested that effects of ginseng on drug
metabolizing enzymes are diverse. In human studies, long-term
(28 d) treatment of ginseng capsule (500 mg, twice daily) induced
the activity of CYP3A in liver and intestine [55]. In another human
study, induction of CYP3A activity was not observed by treatment
of ginseng extract for 14 d, 100 mg, twice daily although low
concentration ginseng activates CYP4A4 in vitro with human liver
microsomes [56]. In addition, ginseng extract induced expression
of CYP3A4 in human primary hepatocyte and increased CYP3A4-
mediated luciferase activity in HepG2 cells expressing luciferase
reporter gene with CYP3A4 promotor [57]. By contrast, the in vitro
study showed that ginseng is capable of inhibiting CYP2C9- and
CYP3A4-mediatedmetabolic reactions in human liver microsomes
[58]. It was also reported that imatinib is a substrate of CYP2C8
and CYP3A4 and imatinib is a potent inhibitor of CYP3A4 as well in
vitro [59].
As a result, more cases are needed to support that notion that
ginseng increases markedly the level of plasma concentration of
imatinib which is able to cause severe hepatotoxicity. Thus, these
notions may not be compatible with the author’s claim that the
imatinibeginseng interaction is responsible for the hepatotoxicity
of an individual who took imatinib and ginseng simultaneously for
a long time.
7. Hypertension
A case study reported that a 64-yr-old male who had never
suffered hypertension taking 500 mg of the P. ginseng preparation
Ginseng Forte-Dietisa for 13 d experienced a transient ischemic
attack (amaurosis fugax) secondary to hypertensive crisis (195/
95 mmHg). One wk after quitting the ginseng product, the blood
pressure was restored to its previous level (< 140/90 mmHg). The
authors claimed for the ﬁrst time that the consumption of Korean
P. ginseng is related to the transient ischemic attack manifesting as
amaurosis fugax by causing the hypertensive crisis [79], which is
rather inconclusive. Instead, more direct evidence such as phar-
macokinetic/pharmacodynamic proﬁle is required to conﬁrm the
ginseng-induced amaurosis fugax although there is a certain tem-
poral coincidence between ginseng intake and changes in blood
pressure.
8. Photohemolysis
Signiﬁcant phototoxicity by ginseng extract was observed in red
blood cells when tested by photohemolysis reaction in vitro [60].9. Reproduction toxicity
The safety issue of ginseng intake during pregnancy has been
always controversial and needs to be resolved. Experiments were
performed to test the possible toxic inﬂuence of ginseng and its
components on the embryogenesis and fetal development of
mouse and rat. Korean Red Ginseng extract which was orally
administered to mice from 2 wk prior to mating to gestational Day
18 did not cause any signiﬁcant developmental toxicity up to
2,000 mg/kg/d, which is approximately 200 times clinical doses,
although the incidence of supernumerary ribs increased at the dose
of 200 mg/kg/d [14].
By contrast, in the experiments with whole embryo cultures,
high concentrations of ginsenoside Rg1 and Rb1 were reported to
cause teratogenicity in rat and mouse, and Re in rat. Rats are more
sensitive than mice to the embryonic toxicity of ginsenoside Rg1
[11,61,62]. In a separate experiment, growth of the hind- and mid-
brains and the caudal neural tube was signiﬁcantly increased by
ginsenoside Rg1, although overall morphological changes in
cultured rat embryo were not observed [10].
However, these observations are challenged by the notion that
the experiments were performed with animal embryos and based
on exposure to isolated ginsenosides at much higher levels than
attainable through usual intake in humans [63]. In addition, ac-
cording to the reports that systematically analyze the effects of
ginseng on reproduction, no side effects are associated with
ginseng used during pregnancy and some androgenic effects re-
ported in the literature are due to an adulterant [63]. Nevertheless,
many commercial ginseng products contain those three ginseno-
sides at relatively high levels and, when extrapolating from the
results of animal studies to humans, ginseng intake might cause
weight loss, as well as mental and behavior disorders of newborns.
Surprisingly, a study showed that about 15% of women consume
ginseng during pregnancy and they assume that ginseng would be
beneﬁcial for the fetus and pregnancy [64]. In the survey to study
characteristics of women using herbal drugs and the possible in-
ﬂuence of use or abuse in early pregnancy on pregnancy outcome,
ginseng is one of the most frequently used herbal medicine and no
notable abnormalities were observed with the consumption of
ginseng in terms of premature delivery, number of newborns,
weight of infants, malformations, and Apgar score [65]. Neverthe-
less, ingestion of ginseng and its products should be avoided during
the ﬁrst trimester of pregnancy and lactation periods.
10. Anticoagulanteginseng interaction
According to Natural Medicines Comprehensive Database,
nearly 180 dietary supplements and medicinal herbs are likely to
interact with warfarin and ginseng is one of them [66,67]. Warfarin,
a narrow margin safety anticoagulant is usually used in the pre-
vention of thrombosis and thromboembolism. These interactions
may enhance or reduce warfarin’s anticoagulation effect [68e70].
Studies reviewing the extensive literature regarding the safety and
pharmacology of ginseng suggest that ginseng usually tends to
cause bleeding [71]. This could be supported by the facts that
various types of ginseng inhibit platelet aggregation and prolong
blood coagulation time in in vitro and experimental animal [72e
74]. Thus, it may enhance the anticoagulant effects of warfarin.
Separate studies have been performed to understand the effect
of various types of ginseng in thrombosis and their interactions
with standard anticoagulant drugs in different clinical settings. In a
reported case, ginseng was able to inhibit the anticoagulant action
of warfarin signiﬁcantly [75]. In the randomized, double-blind,
placebo-controlled trial with a total of 20 healthy patients, Amer-
ican ginseng signiﬁcantly reduced the peak international
Table 1
Patient risks associated with ginseng abuse and misuse
Adverse effects Samples Patients Types of reports Refs
Acute lobular hepatitis Ginseng energy drinks 26-yr-old male leukemia patient Case report [54]
Allergy Asian ginseng syrup. 20-yr-old male patient Case report [31]
Allergy Panax ginseng 29-yr-old female patient Case report [32]
Allergy Korean ginseng extract 44-yr-old man Case report [33]
Allergy Korean ginseng 34-yr-old woman Case report [34]
Atrial ﬁbrillation with bradycardia Asian ginseng 83-yr-old woman with chronic renal insufﬁciency Case report [38]
Gynecomastia Red ginseng extract 12-yr-old boy Case report [46]
Hypertensive crisis Ginseng Forte-Dietisa 64-yr-old male who had never suffered hypertension Case report [79]
Increase in QTc interval and Reduction
of diastolic pressure
P. ginseng extract Total 30 healthy adults Clinical trial [36]
Long QT and torsades de pointes Large amounts of ginseng drink 43-yr-old healthy woman Case report [37]
Manic episode Ginseng root extract 56-yr-old woman with previous affective disorder Case report [22]
Manic episode Chinese red ginseng 26-yr-old healthy individual with no history of
psychiatric illness
Case report [23]
Reduction of warfarin action American ginseng 20 healthy individuals Clinical trial [76]
Uterine bleeding Ginseng cosmetics and ginseng
capsules
39-yr-old woman Case report [47]
Uterine bleeding Pharmaton Complex 48-yr-old woman Case report [48]
J Ginseng Res 2015;39:89e9392normalized ratio (INR) and plasmawarfarin concentration and thus
inhibited warfarin’s anticoagulant activity [76].
In a prospective, double-blind, randomized, two-period cross-
over study, 25 patients with cardiac valve replacement under
warfarin therapy were treated with either Korean Red Ginseng or
placebo and then INR and warfarin concentrations were analyzed
in the 3rd wk and 6th wk of each study period. Results showed that
application of Korean Red Ginseng did not affect the mean INR
changes compared with placebo [77]. Similarly, in the separate
study with ischemic stroke patient ginseng water extract did not
inﬂuence on the action of warfarin [78]. These variations may come
from the types of ginseng and clinical settings. More studies are
required to assess the clinical signiﬁcance of these potential
interactions.
11. Conclusion
Patient risks associated with ginseng abuse and misuse such as
affective disorder, allergy, cardiovascular and renal toxicity, genital
organ bleeding, gynecomastia, hepatotoxicity, hypertension,
reproductive toxicity, and anticoagulanteginseng interaction were
reviewed and summarized. Further investigation in more cases is
required to clarify these issues (Table 1) [22,23,31e34,36e38,46e
48,54,76,79].
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